SS-31 and Barth Syndrome: Clinical Trial Insights

Reviewed for accuracy by the Gorilla Research Labs research team · 2026-07-04

RESEARCH SS-31 and Barth Syndrome: Clinical Trial Insights SS-31, known in clinical settings as elamipretide, has emerged as a focal point in research regarding mitochondrial myopathy and the rare genetic condition Barth syndrome. Clinical investigations continue to evaluate its potential to stabilize mitochondrial membranes and improve cellular bioenergetics in mitochondrial myopathy ^[1] and Barth syndrome ^[3]. Compound identity: CAS 736992-21-5 · C32H49N9O5 · 639.8 g/mol (verified via PubChem)

The Mechanism: Cardiolipin and Mitochondrial Integrity

At the center of the interest in SS-31 is its unique interaction with cardiolipin, a phospholipid essential for the structural integrity of the inner mitochondrial membrane ^[1]. In healthy mitochondria, cardiolipin acts as a scaffold for the electron transport chain complexes; however, in states of oxidative stress, this lipid can become oxidized, leading to mitochondrial dysfunction ^[1]. Research in animal models and in-vitro studies suggests that SS-31 binds to cardiolipin, effectively preventing the formation of reactive oxygen species and maintaining the curvature required for efficient ATP production ^[1]. This mechanism-only evidence provides the foundational hypothesis for why the compound is being investigated in conditions where mitochondrial architecture is fundamentally compromised.

SS-31 Clinical Trials for Mitochondrial Myopathy

The transition from bench science to human application has been marked by rigorous scrutiny. In a randomized, double-blind, placebo-controlled human trial involving patients with primary mitochondrial myopathy, researchers sought to determine if the compound could influence exercise capacity and muscular function ^[2]. While the study provided significant data regarding the safety and tolerability of the compound in human subjects, the primary endpoints—often measured via distance walked or metabolic markers—demonstrated the complexity of translating molecular stabilization into systemic clinical improvement ^[2]. These trials highlight the distinction between the compound's proven ability to stabilize membranes in controlled settings and the multifaceted challenges of treating systemic mitochondrial disease in human populations ^[2].

ReCLAIM-2 Trial Results and Efficacy

The ReCLAIM-2 phase 2 trial represents a critical chapter in the study of elamipretide for individuals living with Barth syndrome ^[3]. This rare, X-linked genetic disorder is characterized by cardiolipin deficiency, which directly impairs mitochondrial function and leads to severe muscle weakness and cardiac issues ^[3]. The ReCLAIM-2 trial results indicated that the compound was generally well-tolerated by the participants ^[3]. However, the data also underscored the difficulty of establishing definitive efficacy metrics in rare disease populations where baseline pathology is highly variable ^[3]. While the trial provided valuable insights into the pharmacokinetics and safety profile of the compound in this specific cohort, it also served as a reminder that clinical outcomes in rare diseases often require long-term, multi-center observation to reach statistical significance ^[3].

Elamipretide FDA Approval Status

The regulatory landscape for elamipretide is currently evolving, particularly regarding its application in rare diseases. Recently, the FDA granted accelerated approval for the treatment of Barth syndrome, recognizing the urgent need for therapeutic options in this population ^[4]. It is important to note that this approval is specific to a defined patient population and is contingent upon further verification of clinical benefit through ongoing research ^[4]. The status of the compound remains a subject of intense focus for clinicians and researchers alike, as they navigate the requirements for long-term data collection following this regulatory milestone ^[4].

Understanding the Limits of Current Data

While the mechanism of SS-31 is well-characterized in in-vitro and animal models, it is essential to distinguish these findings from the outcomes observed in human clinical trials ^[1], ^[2]. The research has not yet established a universal, curative effect for all forms of mitochondrial myopathy, nor have all clinical trials reached the primary efficacy thresholds originally hypothesized ^[2], ^[3]. Furthermore, the data from ReCLAIM-2, while promising in terms of safety and tolerability, represents a specific phase of investigation that must be reconciled with broader, long-term observational studies to fully understand the compound's role in clinical practice ^[3].

Frequently asked questions

What is the current elamipretide FDA approval status? The FDA has granted accelerated approval for elamipretide specifically for the treatment of Barth syndrome in a defined patient population, with ongoing requirements for further clinical verification ^[4]. How does SS-31 function at the cellular level? Based on mechanism-only and in-vitro evidence, SS-31 is thought to bind to cardiolipin, preventing its oxidation and maintaining the structural integrity of the inner mitochondrial membrane, which supports efficient energy production ^[1]. What did the ReCLAIM-2 trial results show? The ReCLAIM-2 phase 2 trial provided data on the safety and tolerability of elamipretide in patients with Barth syndrome, though it also highlighted the challenges of measuring efficacy in rare disease cohorts ^[3]. Are there definitive results from SS-31 clinical trials for mitochondrial myopathy? Clinical trials for primary mitochondrial myopathy have been conducted to assess safety and exercise capacity, but these studies have shown that translating molecular stabilization into systemic clinical improvement remains a complex hurdle ^[2]. Is SS-31 the same as elamipretide? Yes, SS-31 is the research designation for the compound known in clinical trial literature as elamipretide ^[1], ^[2], ^[3], ^[4]. Elamipretide (SS-31) is a cell-permeable peptide that targets the inner mitochondrial membrane to interact with cardiolipin ^[1]. By utilizing lot-specific tracking and rigorous analytical methods, researchers can ensure that the material used in their investigations is consistent, thereby maintaining the validity of the experimental results. Research use only. The compounds discussed are supplied for laboratory research and are not for human or veterinary use. Nothing on this page is medical advice, a dosing guide, or a claim about any product sold here; it summarises published research and cites its sources.